{"id":1901,"company":{"country":"US","currency":"USD","exchange":"NASDAQ NMS - GLOBAL MARKET","ipo":"2017-11-09","marketCap":7451.27685546875,"name":"Apellis Pharmaceuticals Inc","phone":"16179775700","outstanding":118.5,"symbol":"APLS","website":"https://apellis.com/","industry":"Biotechnology"},"price":61.88,"year":2023,"month":12,"day":14,"weekday":"Thursday","title":"Impact of natural disasters and climate-related risks on Apellis Pharmaceuticals Inc stock and its industry","date":"2023-12-14","url":"/posts/2023/12/14/APLS","content":[{"section":"Supply chain disruption","text":"Natural disasters such as hurricanes, floods, and wildfires can disrupt the supply chains of pharmaceutical companies like Apellis Pharmaceuticals Inc. These disruptions can lead to delays in the production and distribution of drugs, which can have a negative impact on the company's stock and overall industry performance."},{"section":"Increased costs","text":"Climate-related risks such as extreme weather events and rising temperatures can increase operating costs for pharmaceutical companies. For example, higher energy costs for cooling systems or the need to ensure the stability of medications during transportation in unfavorable weather conditions can add financial burdens. These increased costs can affect Apellis Pharmaceuticals Inc stock and its industry's profitability."},{"section":"Business operations impact","text":"Natural disasters and climate-related risks can directly impact Apellis Pharmaceuticals Inc's business operations. For instance, facilities may be damaged or rendered inoperable, leading to production shutdowns and revenue losses. Additionally, employee safety can be at risk during extreme weather events, which may disrupt workforce availability and further impact business operations."},{"section":"Climate resilience","text":"As climate-related risks continue to grow, pharmaceutical companies like Apellis Pharmaceuticals Inc need to prioritize climate resilience. This involves implementing strategies to adapt to and mitigate the impacts of natural disasters and climate-related risks. These strategies may include diversifying supply chains, investing in backup power systems, adopting sustainable practices, and considering the potential effects of climate change on drug development. By enhancing climate resilience, Apellis Pharmaceuticals Inc and its industry can better safeguard their operations and stock performance."},{"section":"Regulatory and market trends","text":"Furthermore, increased awareness and focus on climate-related risks from both regulators and consumers can shape the pharmaceutical industry's overall performance. Regulatory actions and incentives to promote climate resilience and sustainability may impact the stock performance of companies like Apellis Pharmaceuticals Inc. Moreover, consumer preference for environmentally conscious and socially responsible companies can influence market trends and investor sentiment towards the industry."}],"tags":["CrossOver55","Long","Biotechnology"],"news":[{"category":"company","date":1702537262,"headline":"Apellis Provides Update on Ongoing Regulatory Review of Pegcetacoplan for GA in the European Union","id":124508460,"image":"","symbol":"APLS","publisher":"Finnhub","summary":"Conference call today at 8:30 a.m. ET WALTHAM, Mass., Dec. 14, 2023 -- Apellis Pharmaceuticals, Inc. announced today an update on the ongoing review of its marketing authorization application for...","url":"https://finnhub.io/api/news?id=7306ee72f18dd153cd65e0fb5cd85e2b7db77109ebe449169a7552d50780dd2f"},{"category":"company","date":1702449360,"headline":"Maintaining Buy Rating on Apellis Pharmaceuticals: Confidence in EU Approval and Long-Term Market Potential for Syfovre","id":124504148,"image":"","symbol":"APLS","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3255902137"},{"category":"company","date":1702377060,"headline":"Interesting APLS Put And Call Options For February 2024","id":124474735,"image":"","symbol":"APLS","publisher":"Stock Options Channel","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3253409825"},{"category":"company","date":1702362105,"headline":"Apellis Pharmaceuticals, Inc. - EMPAVELI Provided Long-Term Control of PNH in New Data Presented at ASH Annual Meeting","id":124455362,"image":"","symbol":"APLS","publisher":"Finnhub","summary":"WALTHAM - Apellis Pharmaceuticals, Inc. and Sobi today presented post hoc data that reinforce the long-term efficacy and safety of EMPAVELI in adults with paroxysmal nocturnal hemoglobinuria for...","url":"https://finnhub.io/api/news?id=f57df9b2d288b551a8af1eee7b019e910df3d7625bcfac3022690b5a792c5928"},{"category":"company","date":1702297020,"headline":"Why bluebird bio Shares Are Trading Higher? Here Are Other Stocks Moving In Monday's Mid-Day Session","id":124440107,"image":"","symbol":"APLS","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3251695393"},{"category":"company","date":1702296000,"headline":"EMPAVELI® (pegcetacoplan) Provided Long-Term Control of PNH in New Data Presented at ASH Annual Meeting","id":124437399,"image":"https://media.zenfs.com/en/globenewswire.com/ee6969fd8bbd71bc3d94e172ead4fbb7","symbol":"APLS","publisher":"Yahoo","summary":"Rapid improvements in key markers of disease were sustained for up to three years across all adults with PNHMajority of patients remained transfusion free over the long termZero cases of meningococcal infection observed over three years in this analysisData shared during an oral presentation WALTHAM, Mass., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi today presented post hoc data that reinforce the long-term efficacy and safety of EMPAVELI® (pegcetacop","url":"https://finance.yahoo.com/news/empaveli-pegcetacoplan-provided-long-term-120000594.html"},{"category":"company","date":1702291200,"headline":"Apellis Pharmaceuticals Breaks Below 200-Day Moving Average - Notable for APLS","id":124445350,"image":"","symbol":"APLS","publisher":"Market News Video","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3251557290"},{"category":"company","date":1702289400,"headline":"Coinbase, Riot Platforms, Marathon Digital And Other Big Stocks Moving Lower On Monday","id":124437735,"image":"","symbol":"APLS","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3251517096"},{"category":"company","date":1702274880,"headline":"Apellis says EMPAVELI provided long-term control of PNH","id":124445353,"image":"","symbol":"APLS","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3251231802"},{"category":"company","date":1701934465,"headline":"Apellis Pharmaceuticals Announces Inducement Grants under Nasdaq Listing Rule 5635(4)","id":124357357,"image":"","symbol":"APLS","publisher":"Finnhub","summary":"WALTHAM - Apellis Pharmaceuticals, Inc. , today announced that the company approved the grant of equity awards to 4 new employees with a grant date of December 1, 2023, as equity inducement awards...","url":"https://finnhub.io/api/news?id=ea6cfb6ce22a6625af47a27f9eb32dc3c8ae6294591a0ad5580fd95f96931f92"},{"category":"company","date":1701896700,"headline":"Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","id":124352319,"image":"https://media.zenfs.com/en/globenewswire.com/ee6969fd8bbd71bc3d94e172ead4fbb7","symbol":"APLS","publisher":"Yahoo","summary":"WALTHAM Mass., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), today announced that the company approved the grant of equity awards to 4 new employees with a grant date of December 1, 2023, as equity inducement awards outside of the company's 2017 Stock Incentive Plan (but under the terms of the 2020 Inducement Stock Incentive Plan) and material to the employees’ acceptance of employment with the company. The equity awards were approved in accordance with Nasdaq L","url":"https://finance.yahoo.com/news/apellis-pharmaceuticals-announces-inducement-grants-210500614.html"},{"category":"company","date":1701861576,"headline":"Apellis Pharmaceuticals: Focus Shifts Toward Market Share After Apparent Safety Resolution","id":124333149,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1432339380/image_1432339380.jpg?io=getty-c-w1536","symbol":"APLS","publisher":"SeekingAlpha","summary":"Apellis' safety improvements and market potential for Syfovre, the first GA treatment, are weighed against uncertainties. Click here to read more about APLS.","url":"https://seekingalpha.com/article/4656329-apellis-pharma-focus-shifts-toward-market-share-after-safety-resolution"},{"category":"company","date":1701786303,"headline":"What Mid-Cap Stocks Are Institutions And Hedge Funds Buying?","id":124310605,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/926069614/image_926069614.jpg?io=getty-c-w1536","symbol":"APLS","publisher":"SeekingAlpha","summary":"Discover the top mid-cap winners from 13F filings in Q3, gaining insights and improving investment decisions based on sentiment analysis. Click here to read.","url":"https://seekingalpha.com/article/4656110-what-mid-cap-stocks-are-institutions-and-hedge-funds-buying"},{"category":"company","date":1701785735,"headline":"B of A Securities Upgrades Apellis Pharmaceuticals (APLS)","id":124301784,"image":"","symbol":"APLS","publisher":"Fintel","summary":"","url":"https://fintel.io/news/b-of-a-securities-upgrades-apellis-pharmaceuticals-apls-175"},{"category":"company","date":1701774360,"headline":"What You Missed On Wall Street This Morning","id":124305615,"image":"","symbol":"APLS","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3242417660"},{"category":"company","date":1701766320,"headline":"Lululemon downgraded, Datadog initiated: Wall Street's top analyst calls","id":124304011,"image":"","symbol":"APLS","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3242241532"},{"category":"company","date":1701761400,"headline":"S\u0026P 500 Futures Drop in Premarket Trading; GitLab, Core \u0026 Main Lead","id":124314581,"image":"https://s.wsj.net/public/resources/MWimages/MW-HA919_barron_NS_20181226134502.png","symbol":"APLS","publisher":"MarketWatch","summary":"With U.S. stock markets set to open in two hours, (GTLB) was up 14.0% in pre-market trading, and (CNM) was up 4.0%. (APLS), (CNXC), and (SJM) were all...","url":"https://www.marketwatch.com/articles/s-p-500-futures-drop-in-premarket-trading-gitlab-core-main-lead-f17652b5"},{"category":"company","date":1701759960,"headline":"14 Analysts Have This to Say About Apellis Pharmaceuticals","id":124318321,"image":"","symbol":"APLS","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3242116659"},{"category":"company","date":1701758086,"headline":"Nike assumed at Buy, 'near-term challenges well understood': 4 big analyst picks","id":124303476,"image":"https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png","symbol":"APLS","publisher":"Yahoo","summary":"Here is your Pro Recap of the biggest analyst picks you may have missed since yesterday: Buy assumptions at Nike and Block, and upgrades at Crown Castle and Apellis Pharmaceuticals.  Goldman Sachs assumed coverage on  Nike  (NYSE:NKE) with a Buy rating and a price target of $139.00 (from $136 prior), as reported in real-time on InvestingPro.  The analysts expect an upturn in Nike's earnings growth.","url":"https://finance.yahoo.com/news/nike-assumed-buy-near-term-063446573.html"},{"category":"company","date":1701757500,"headline":"Block To Rally Around 54%? Here Are 10 Top Analyst Forecasts For Tuesday","id":124303517,"image":"","symbol":"APLS","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3242075207"},{"category":"company","date":1701747180,"headline":"What You Missed On Wall Street On Tuesday","id":124315590,"image":"","symbol":"APLS","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3242805394"},{"category":"company","date":1701740400,"headline":"Apellis Pharmaceuticals Upgraded To Buy: Analyst Sees Potential In Syfovre's Strong Launch","id":124318324,"image":"","symbol":"APLS","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3242634828"},{"category":"company","date":1701739980,"headline":"Analysts Offer Insights on Healthcare Companies: Apellis Pharmaceuticals (APLS), Neurocrine (NBIX) and UnitedHealth (UNH)","id":124304757,"image":"","symbol":"APLS","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3241846703"},{"category":"company","date":1701704700,"headline":"Apellis (APLS) Rides on Syfovre to Fuel Growth Amid Rivalry","id":124294919,"image":"https://media.zenfs.com/en/zacks.com/4a0e141116a5c1fff5e57140486a1890","symbol":"APLS","publisher":"Yahoo","summary":"Apellis' (APLS) marketed products, Syfovre and Empaveli, continue to remain the growth drivers since launch. However, stiff competition in the target markets remains a woe.","url":"https://finance.yahoo.com/news/apellis-apls-rides-syfovre-fuel-154500359.html"},{"category":"company","date":1701684480,"headline":"Biotech Alert: Searches spiking for these stocks today","id":124283362,"image":"","symbol":"APLS","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3240604843"},{"category":"company","date":1701672660,"headline":"Apellis upgraded to Buy at BofA on safety profile for Syfovre","id":124318329,"image":"","symbol":"APLS","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3241345218"},{"category":"company","date":1701663660,"headline":"Analysts Conflicted on These Healthcare Names: Pfizer (PFE), Apellis Pharmaceuticals (APLS) and Bausch + Lomb Corporation (BLCO)","id":124278182,"image":"","symbol":"APLS","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3240262437"},{"category":"company","date":1701661080,"headline":"Apellis upgraded to Buy from Neutral at BofA","id":124318330,"image":"","symbol":"APLS","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3241048178"},{"category":"company","date":1701599820,"headline":"Positive Outlook for Apellis Pharmaceuticals with Buy Rating and Anticipated Share Price Return","id":124265142,"image":"","symbol":"APLS","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3239602802"},{"category":"company","date":1701448313,"headline":"Apellis Pharmaceuticals, Inc. (APLS) Up 9.2% Since Last Earnings Report: Can It Continue?","id":124242578,"image":"https://media.zenfs.com/en/zacks.com/7853de8d69faeccb7d1ad6ebba40b8a2","symbol":"APLS","publisher":"Yahoo","summary":"Apellis Pharmaceuticals, Inc. (APLS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.","url":"https://finance.yahoo.com/news/apellis-pharmaceuticals-inc-apls-9-163153441.html"},{"category":"company","date":1701421020,"headline":"FDA issues anticipated revised label for Apellis' Syfovre, says Wedbush","id":124230379,"image":"","symbol":"APLS","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3236974141"},{"category":"company","date":1701418800,"headline":"Apellis adds safety warning to eye therapy","id":124229871,"image":"","symbol":"APLS","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3236932729"},{"category":"company","date":1701392700,"headline":"Raymond James sticks with 'Street-high' Apellis estimate after update","id":124252772,"image":"","symbol":"APLS","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3237279891"},{"category":"company","date":1701342579,"headline":"Apellis Pharmaceuticals' (NASDAQ:APLS) growing losses don't faze investors as the stock rises 5.6% this past week","id":124198101,"image":"https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305","symbol":"APLS","publisher":"Yahoo","summary":"When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose...","url":"https://finance.yahoo.com/news/apellis-pharmaceuticals-nasdaq-apls-growing-110939174.html"}]}